COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment.

AIMS Although aspirin treatment is useful in reducing ischaemic events in diabetic patients, recent studies suggest that it is less effective when compared with non-diabetics (ND). We sought to evaluate COX-1 sensitivity and thromboxane A(2) (TxA(2)) production in type 1 (T1DM) and type 2 diabetic (T2DM) patients under chronic aspirin treatment, and also evaluate the association between thromboxane A(2) (TxA(2)) production and markers of inflammation and metabolic control, such as high-sensitivity C-reactive protein, fasting blood glucose, and haemoglobin A1c (HbA1c). METHODS AND RESULTS Agonist-induced platelet aggregation (PA) and TxB(2), a stable metabolite of TxA(2), production, serum TxB(2), and platelet COX-1 and COX-2 expression were studied in T2DM patients, T1DM patients, and high-risk ND subjects, all receiving a low dose of aspirin. TxB(2) formation was studied in platelets treated in vitro with aspirin alone or with a COX-2 inhibitor (NS-398). PA, collagen-induced TxB(2) production, and serum TxB(2) were higher in T1DM and T2DM patients than in ND subjects. TxB(2) production was reduced in diabetic patients by in vitro treatment with aspirin. COX-2 was expressed in all diabetic patients but only in 46% of ND patients. In diabetic patients significant correlations were observed between TxB(2) production and both fasting plasma glucose and HbA1c. CONCLUSION COX-1 sensitivity and TxB(2) production is similarly reduced in both T1DM and T2DM patients under chronic aspirin treatment. The association between TxB(2) production and either fasting plasma glucose and HbA1c levels suggests that in diabetic patients hyperglycaemia is a determinant of the reduced platelet sensitivity to aspirin.

[1]  久雄 小川.  Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes（JPAD）Trial , 2011 .

[2]  T. Morimoto,et al.  Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes , 2012 .

[3]  J. Sieradzki,et al.  Effect of atorvastatin on endothelial function and inflammation in long‐duration type 1 diabetic patients without coronary heart disease and arterial hypertension , 2008, Diabetes, obesity & metabolism.

[4]  G. Rossi,et al.  Diagnosis and Classification of Diabetes Mellitus The information that follows is based largely on the reports of the Expert Committee on the Diagnosis and Classification of Diabetes (Diabetes Care 20:1183–1197, 1997, and Diabetes Care 26:3160–3167, 2003). , 2008, Diabetes Care.

[5]  C. Macaya,et al.  Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. , 2007, Journal of the American College of Cardiology.

[6]  P. Sager,et al.  Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). , 2007, The American journal of cardiology.

[7]  N. Dowling,et al.  More on: aspirin resistance: position paper of the Working Group on Aspirin Resistance. Proposal for a Laboratory Test Guiding Algorithm , 2006 .

[8]  C. Macaya,et al.  Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. , 2006, The American journal of cardiology.

[9]  F. Violi,et al.  Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin , 2005, Journal of thrombosis and haemostasis : JTH.

[10]  C. Macaya,et al.  Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. , 2005, Diabetes.

[11]  J. Eikelboom,et al.  Aspirin resistance: position paper of the Working Group on Aspirin Resistance , 2005, Journal of thrombosis and haemostasis : JTH.

[12]  M. Czyz,et al.  Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin , 2005, Journal of Molecular Medicine.

[13]  G. Davı̀,et al.  Platelet activation in type 2 diabetes mellitus , 2004, Journal of thrombosis and haemostasis : JTH.

[14]  Deepak L. Bhatt,et al.  Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. , 2004, American heart journal.

[15]  P. Gazzaniga,et al.  Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. , 2004, Journal of the American College of Cardiology.

[16]  R. Natarajan,et al.  Molecular mechanisms of high glucose-induced cyclooxygenase-2 expression in monocytes. , 2004, Diabetes.

[17]  J. Drzewoski,et al.  Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. , 2004, Thrombosis research.

[18]  G. FitzGerald,et al.  Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[19]  M. Roncaglioni,et al.  Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. , 2003, Diabetes care.

[20]  A. Castelnuovo,et al.  Pharmacokinetic and Pharmacodynamic Differences Between Two Low Dosages of Aspirin May Affect Therapeutic Outcomes , 2003, Clinical pharmacokinetics.

[21]  C. Patrono,et al.  Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  A. Connor,et al.  The way I see it: House officers need formal career development , 2002 .

[23]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[24]  K. Schrör,et al.  Towards a definition of aspirin resistance: a typological approach , 2002, Platelets.

[25]  M. Percival,et al.  A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  G. Caughey,et al.  Assay of cyclooxygenase-1 and 2 in human monocytes , 2000, Inflammation Research.

[27]  J. Vane,et al.  Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  C. Watala,et al.  Decreased Platelet Membrane Fluidity Due to Glycation or Acetylation of Membrane Proteins , 1992, Thrombosis and Haemostasis.

[29]  F. Ferris.  Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. , 1992, JAMA.

[30]  E. Klein,et al.  The function of human NK cells is enhanced by β‐glucan, a ligand of CR3 (CD11b/CD18) , 1991, European journal of immunology.

[31]  G. Davı̀,et al.  Thromboxane biosynthesis and platelet function in type II diabetes mellitus. , 1990, The New England journal of medicine.

[32]  F. Gaspari,et al.  Determination of Aspirin and Salicylic Acid in Uremic Patients' Plasma Using Reversed‐Phase High‐Performance Liquid Chromatography , 1987, Therapeutic drug monitoring.

[33]  A. Cerbone,et al.  Trial of repeated low-dose aspirin in diabetic angiopathy. , 1986, Blood.